Please login to the form below

Not currently logged in
Email:
Password:

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

Astellas Claire ThomDr Claire Thom has left her role at Takeda to join rival Japanese pharma company Astellas as senior VP of global oncology development.

Dr Thom was most recently senior VP portfolio management, drug development management and strategic business operations at Millennium, the oncology-focused subsidiary of Takeda.

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

At Millennium Dr Thom will have worked on Velcade, a drug co-developed with Johnson & Johnson (J&J) that is used in blood cancer.

"We're thrilled that Claire is joining our experienced oncology team at Astellas," said Dr Sef Kurstjens, chief medical officer of Astellas.

“We believe that her unique background and varied experience, along with her approach to leadership and management will support our mission to become a global category leader in oncology."

Prior to joining Millennium, Dr Thom served for several years at Takeda itself, including holding responsibility for the oversight and implementation of the global therapeutic area strategies for the company's oncology, urology and gynaecology franchises.

14th August 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics